Table 2 ∣.

Endpoints of efficacy and failure at weeks 48 and 192

	Week 48			Week 192
	Lam & Adv (n = 22)	Adv (n = 19)	P-value	Lam & Adv (n = 22)	Adv (n = 19)	P-value*
Normal ALT	86%	53%	0.037	95%	63%	0.016
HBV DNA Mean ± s.d. change (log10 copies/mL)	−6.8 ± 2.1	−4.5 ± 2.7	0.0048‡	−5.6 ± 1.6	−3.0 ± 2.8	0.0006†
HBV DNA <105 copies/mL	91%	53%	0.007	91%	53%	0.007
HBV DNA <500 copies/mL	68%	53%	0.35	77%	32%	0.005
HBeAg loss	41%	21%	0.28	76%	36%	0.03
HBsAg loss	0%	5%	0.46	0%	5%	0.46
Histological response‡	67% (14/21)	53% (10/19)	0.52	83% (15/18)	56% (5/9)	0.18
Genotypic resistance	0%	0%		0%	32%	0.03
Treatment failure	9%	37%	0.06	18%	68%	0.002
Combined response§	59%	26%	0.058	68%	31%	0.03

^*Fisher exact test.

^†Student’s t-test.

^‡Liver histology was not available on all enroled patients at 48 and 192 weeks; actual numbers given in parentheses. The last result before censoring was used for the week 192 results for subjects who were censored (two in the combination group and nine in the monotherapy group).

^§Primary endpoint.